• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 17, 2014

View Archived Issues

Mixed signals reported from crenezumab trials in Alzheimer's

Crenezumab, an anti-amyloid β (Abeta) antibody which Genentech in-licensed from AC Immune SA, failed to reach the primary endpoint of two phase II studies in Alzheimer's disease, but the drug has demonstrated tantalizing signs of efficacy in patients at the milder end of the Alzheimer's spectrum. Read More

Rigel phase III takes fostamatinib to bat against bleeding disorder

Following Astrazeneca plc's decision to return fostamatinib rights to Rigel Pharmaceuticals Inc. last year, Rigel is pushing ahead with twin phase III studies of the oral spleen tyrosine kinase (SYK) inhibitor in patients with the tough-to-beat bleeding disorder, immune thrombocytopenic purpura (ITP). Read More

HD Biosciences, Marshall partner to develop drugs for kidney fibrosis, cancer

SHANGHAI – HD Biosciences Co. Ltd. has signed an agreement to co-develop drugs with two research centers at Marshall University. The deal was struck after three years of informal collaboration between both sides, and with an eye to entering the clinic in the next two years. The focus of the alliance is to provide innovative medicines for unmet medical needs, particularly cancer and kidney fibrosis, in both China and the U.S. Read More

Immunocore signs Eli Lilly in fourth T-cell collaboration

LONDON – The deals go on for Immunocore Ltd., which has signed Eli Lilly and Co. as the fourth partner in little over a year for its Immtac T-cell receptor technology. Read More

Two-pronged Amyndas targets complement-based anti-inflammatories

Researcher John Lambris has devoted his career of more than 30 years to exploring the human complement system. His lab at the University of Pennsylvania, where Lambris serves as professor of research medicine in the department of pathology and laboratory medicine, was among the first in the world to map the critical sites on the human C3 protein that are responsible for its many functions and to define its complex binding dynamics to various C3 natural ligands. Read More

Xencor's CEO updates progress with RA, asthma, allergic disease candidates

Xencor Inc. at the end of 2013 raised $70 million with its initial public offering. The funds were targeted to support clinical development of FC-engineered antibody candidates XmAb5871 and XmAb7195. Read More

News from Washington

The FDA released a draft guidance on informed consent that, when finalized, will update a guidance issued in 1998. The draft describes general requirements, basic and additional elements of informed consent, documentation, and responsibilities of the FDA, sponsor, investigator and institutional review board. Read More

Financings

Immatics Biotechnologies GmbH, of Tuebingen, Germany, said it received €22 million (US$29.77 million) to complete a series D financing round. Read More

Stock movers

Read More

Other news to note

Cara Therapeutics Inc., of Shelton, Conn., said it earned a $500,000 milestone payment from Maruishi Pharmaceutical Co. Ltd., of Osaka, Japan, for the completion of its phase I trial of the I.V. formulation of Cara's kappa opioid agonist, CR845, in Japan. Read More

In the clinic

Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., reported interim data from the phase IV PRISM II study, showing that treatment with Nuedexta (dextromethorphan hydrobromide) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's. Read More

Pharma: Other news to note

Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., said the FDA has granted breakthrough therapy designation to nintedanib, a tyrosine kinase inhibitor, currently under FDA review. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe